Citations

Clear

431 citation(s) found for "Schmidt, C".

Outcomes of Simultaneous Liver–Kidney Transplant Recipients According to Pre-Transplant Transjugular Intrahepatic Portosystemic Shunt (TIPS) in the United States
Meier, Tristan, Schmidt, Kathryn, Mara, Kristin C. , Olson, Jody C. , Taner, Timuçin , Riad, Samy , Riad, Samy M. , Taner, Timucin , Mara, Kristin C , Meier, Tristan , Simonetto, Douglas A.

Mayo Clinic

Transplantology | October 17, 2024 | Volume: 5 | Issue: 4 | Pages: 234-245

10.3390/transplantology5040023 Get It

Background: Previous data suggested that the outcomes for liver-alone transplant recipients following transjugular intrahepatic portosystemic shunt (TIPS) insertion were comparable to those without TIPS. This study investigates the association between TIPS and outcomes among simultaneous liver–kidney (SLK) recipients in the United States. Methods: Utilizing the Scientific Registry for Transplant Recipients (SRTR) standard analysis file from 2003 to 2022, we examined 9717 adult SLK recipients, among whom 858 had undergone TIPS before transplantation. Kaplan–Meier curves were generated to assess recipient and death-censored liver and kidney graft survival. Mixed-effects Cox proportional hazard models were employed to analyze the association between TIPS and the outcomes of interest, where the transplant center was treated as a random effect. The models were adjusted for recipient age, sex, MELD score, diabetes, duration of listing, induction, steroid maintenance, hepatitis C status, donor age, donor sex, cold ischemia time, local vs. shipped organs, and allocation era. Results: Overall, the two groups were comparable, with minor differences. Notably, the median liver waiting time was significantly longer in the TIPS group compared to the non-TIPS group (4.1 vs. 2 months, p < 0.001). One-year rejection rates for liver and kidney allografts did not differ significantly between groups. Univariable Cox regression analyses demonstrated no association between TIPS and worse outcomes for recipient, liver, and kidney survival (p = 0.65, p = 0.22, and p = 0.54, respectively). TIPS did not emerge as a predictor of recipient or death-censored liver or kidney graft survival in multivariable models. Conclusion: In this extensive national cohort of SLK transplant recipients, pre-transplant TIPS was not linked to adverse outcomes for recipients or their allografts.
V-310.4: Outcomes of simultaneous liver kidney transplant recipients according to pre-transplant transjugular intrahepatic portosystemic shunt (TIPS) in the United States
Meier, Tristan, Schmidt, Kathryn, Cole, Kristin, Olson, Jody C. , Taner, Timucin, Meier, Tristan, Cole, Kristin, Simonetto, Douglas A. , Riad, Samy

Mayo Clinic

Transplantation | September 16, 2024 | Volume: 108 | Issue: 9S | Pages: No page available

10.1097/01.tp.0001066848.22361.76 Get It

Roadmap to a Global Template for Implementation of Ototoxicity Management for Cancer Treatment
Fernandez, Katharine , Hoetink, Alex E. , Berndtson, Deborah, Clark, Khaya D. , Dreisbach, Laura , Grosnik, Amy, Jamis, Carmen, Lee, John , Liberman, Patrícia Helena Pecora, Milnes, Trisha, Meijer, Annelot J. M. , Ortiz, Candice E., Rooker, Jennessa , Heuvel-Eibrink, Mary M. van den, Brewer, Carmen C. , Poling, Gayla L. , Clark, Khaya , Konrad‐Martin, Dawn , Geller, James I. , Goffi-Gómez, María Valéria Schmidt , Knight, Kristin R. , Lee, David S. , Sanchez, Victoria A , Heuvel‐Eibrink, Mary M. van den

Mayo Clinic

Ear & Hearing | September 12, 2024 | Volume: 46 | Issue: 2 | Pages: 286-297

10.1097/aud.0000000000001592 | PMID 39261989 Get It

Ototoxicity is among the adverse events related to cancer treatment that can have far-reaching consequences and negative impacts on quality-of-life for cancer patients and survivors of all ages. Ototoxicity management (OtoM) comprises the prevention, diagnosis, monitoring, and treatment, including rehabilitation and therapeutic intervention, of individuals who experience hearing loss, tinnitus, or balance/vestibular difficulties following exposures to ototoxic agents, including platinum chemotherapy (cisplatin, carboplatin) and cranial radiation. Despite the well-established physical, socioeconomic, and psychological consequences of hearing and balance dysfunction, there are no widely adopted standards for clinical management of cancer treatment-related ototoxicity. Consensus recommendations and a roadmap are needed to guide development of effective and feasible OtoM programs, direct research efforts, address the needs of caregivers and patients at all stages of cancer care and survivorship. Here we review current evidence and propose near-term to longer-term goals to advance OtoM in five strategic areas: (1) beneficiary awareness, empowerment, and engagement, (2) workforce enhancement, (3) program development, (4) policy, funding, and sustainability, and (5) research and evaluation. The goal is to identify needs and establish a roadmap to guide worldwide adoption of standardized OtoM for cancer treatment and improved outcomes for patients and survivors.
Half-Life and Clearance of Cardiac Troponin I and Troponin T in Humans
Kristensen, Jonas Henrik , Hasselbalch, Rasmus Bo , Strandkjær, Nina , Jørgensen, Nicoline, Østergaard, Morten, Møller‐Sørensen, Hasse , Nilsson, Jens Christian , Kamstrup, Pia R. , Dahl, Morten , Bor, Mustafa Vakur , Rode, Line , Holmvang, Lene , Bang, Lia E., Forman, Julie Lyng , Jaffe, Allan S. , Thygesen, Kristian , Bundgaard, Henning , Iversen, Kasper , Møller-Sørensen, Peter Hasse , Afzal, Shoaib , Kamstrup, Pia Rørbæk , Dahl, Morten , Frikke-Schmidt, Ruth , Jørgensen, Niklas Rye , Rode, Line , Kjærgaard, Jesper , Forman, Julie , Dalhoff, Kim , Jaffe, Allan S. , Bundgaard, Henning , Iversen, Kasper Karmark , Jørgensen, Niklas Rye , Kjærgaard, Jesper

Mayo Clinic

Circulation | September 10, 2024 | Volume: 150 | Issue: 15 | Pages: 1187-1198

10.1161/circulationaha.123.066565 | PMID 39253802 Get It

BACKGROUND: Cardiac troponin (cTn) is key in diagnosing myocardial infarction (MI). After MI, the clinically observed half-life of cTn has been reported to be 7 to 20 hours, but this estimate reflects the combined elimination and simultaneous release of cTn from cardiomyocytes. More precise timing of myocardial injuries necessitates separation of these 2 components. We used a novel method for determination of isolated cTn elimination kinetics in humans. METHODS: Patients with MI were included within 24 hours after revascularization and underwent plasmapheresis to obtain plasma with a high cTn concentration. After at least 3 weeks, patients returned for an autologous plasma retransfusion followed by blood sampling for 8 hours. cTn was measured with 5 different high-sensitivity cTn assays. RESULTS: Of 25 included patients, 20 participants (mean age, 64.5 years; SD, 8.2 years; 4 women [20%]) received a retransfusion after a median of 5.8 weeks (interquartile range, 5.0–6.9 weeks) after MI. After retransfusion of a median of 620 mL (range, 180–679 mL) autologous plasma, the concentration of cTn in participants’ blood increased 4 to 445 times above the upper reference level of the 5 high-sensitivity cTn assays. The median elimination half-life ranged from 134.1 minutes (95% CI, 117.8–168.0) for the Elecsys high-sensitivity cTnT assay to 239.7 minutes (95% CI, 153.7–295.1) for the Vitros high-sensitivity cTnI assay. The median clearance of cTnI ranged from 40.3 mL/min (95% CI, 32.0–44.9) to 52.7 mL/min (95% CI, 42.2–57.8). The clearance of cTnT was 77.0 mL/min (95% CI, 45.2–95.0). CONCLUSIONS: This novel method showed that the elimination half-life of cTnI and cTnT was 5 to 16 hours shorter than previously reported. This indicates a considerably longer duration of cardiomyocyte cTn release after MI than previously thought. Improved knowledge of timing of myocardial injury may call for changes in the management of MI and other disorders with myocardial injury.
A Multiomics, Molecular Atlas of Breast Cancer Survivors
Bauer, Brent A. , Schmidt, Caleb M., Ruddy, Kathryn J. , Meydan, Cem , Schmidt, Julian C., Smith, S. , Couch, Fergus J., Earls, John C. , Dudley, Joel T. , Mason, Christopher E. , Zhang, Bodi, Phipps, Stephen M., Schmidt, Michael A. , Dudley, Joel T , Mason, Christopher E , Schmidt, Michael A , Meydan, Cem , Olson, Janet E. , Price, Nathan D.

Mayo Clinic

Metabolites | July 22, 2024 | Volume: 14 | Issue: 7 | Pages: 396

10.3390/metabo14070396 | PMID 39057719 Get It

Breast cancer imposes a significant burden globally. While the survival rate is steadily improving, much remains to be elucidated. This observational, single time point, multiomic study utilizing genomics, proteomics, targeted and untargeted metabolomics, and metagenomics in a breast cancer survivor (BCS) and age-matched healthy control cohort (N = 100) provides deep molecular phenotyping of breast cancer survivors. In this study, the BCS cohort had significantly higher polygenic risk scores for breast cancer than the control group. Carnitine and hexanoyl carnitine were significantly different. Several bile acid and fatty acid metabolites were significantly dissimilar, most notably the Omega-3 Index (O3I) (significantly lower in BCS). Proteomic and metagenomic analyses identified group and pathway differences, which warrant further investigation. The database built from this study contributes a wealth of data on breast cancer survivorship where there has been a paucity, affording the ability to identify patterns and novel insights that can drive new hypotheses and inform future research. Expansion of this database in the treatment-naïve, newly diagnosed, controlling for treatment confounders, and through the disease progression, can be leveraged to profile and contextualize breast cancer and breast cancer survivorship, potentially leading to the development of new strategies to combat this disease and improve the quality of life for its victims.
Design, implementation, and impact of a cirrhosis-specific remote patient monitoring program
Penrice, Daniel D. , Hara, Kamalpreet S. , Chara, Beatriz Sordi , Kezer, Camille A. , Schmidt, Kathryn A. , Kassmeyer, Blake , Lennon, Ryan J. , Rosedahl, Jordan K., Roellinger, Daniel , Rattan, Puru , Williams, Katherine, Leuenberger, Angela , Kamath, Patrick S. , Shah, Vijay H. , Sordi Chara, Beatriz , Kezer, Camille , Schmidt, Kathryn, Lennon, Ryan, Rosedahl, Jordan, Kloft-Nelson, Sara, Kamath, Patrick S , Simonetto, Douglas A , Penrice, Daniel , Lennon, Ryan J. , Kloft‐Nelson, Sara M. , Simonetto, Douglas A.

Mayo Clinic

Hepatology Communications | July 22, 2024 | Volume: 8 | Issue: 8 | Pages: No page available

10.1097/hc9.0000000000000498 | PMID 39037370 Get It

Background: Remote patient monitoring (RPM) is an emerging focus in health care, and specialized programs may reduce medical costs, supplement in-office visits, and improve patient satisfaction. In this study, we describe the development, feasibility, and early outcomes of an RPM program for patients with decompensated cirrhosis. Methods: Forty-six patients were offered enrollment at the time of hospital discharge in the cirrhosis RPM program (CiRPM), of which 41 completed at least 30 days of monitoring. Participants were mailed remote monitoring equipment and a tablet to be used for patient-reported outcomes. Alerts were continuously monitored by virtual nursing staff who could perform targeted interventions. A cohort of historical controls (n = 74) was created for comparison using inverse probability of treatment weighting. Results: Patients were enrolled in the program for a mean of 83.9 days, with 28 (68%) completing the full 90-day program. Participants uploaded vital signs and responded to symptom-based questionnaires on 93% of the monitored days. On end-of-program surveys, over 75% of patients expressed satisfaction with the program. Gender, age, and MELD-Na were similar between CiRPM and weighted control groups. The 90-day readmission rate was 34% in CiRPM and 47% in weighted controls. In the CiRPM group, 12% of subjects had 2 or more admissions, compared to 37% in the weighted control group. Conclusion: This study demonstrates the feasibility of a cirrhosis-specific RPM program. Overall, patient satisfaction and utilization of the CiRPM was high. Future studies are needed to confirm the impact of RPM on the reduction of hospital readmissions in decompensated cirrhosis.
At what COST?: A prospective longitudinal cohort assessment of financial toxicity, quality of life, and associated risk factors in patients with plasma cell disorders
Warsame, Rahma , Schmidt, Walker M. , Dueck, Amylou C. , Dueck, A. C. , Warsame, Rahma , Dispenzieri, Angela , Dispenzieri, Angela

Mayo Clinic

American Journal of Hematology | July 5, 2024 | Volume: 99 | Issue: 10 | Pages: 2029-2031

10.1002/ajh.27431 | PMID 38966949 Get It

Author response: Germline cis variant determines epigenetic regulation of the anti-cancer drug metabolism gene dihydropyrimidine dehydrogenase (DPYD)
Zhang, Ting , Ambrodji, Alisa , Huang, Huixing, Etheridge, Amy S. , Schmidt, Remington E. , Bembenek, Brianna M. , Temesgen, Zoey B., Innocenti, Federico , Diasio, Robert B. , Largiadèr, Carlo R. , Offer, Steven M. , Largiadèr, Carlo R , Offer, Steven M , Bouchonville, Kelly J. , Wang, Zhiquan , Stroka, Deborah

Mayo Clinic

No container title available | April 30, 2024 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.7554/elife.94075.3.sa2 Get It

Germline cis variant determines epigenetic regulation of the anti-cancer drug metabolism gene dihydropyrimidine dehydrogenase (DPYD)
Zhang, Ting , Ambrodji, Alisa , Huang, Huixing, Etheridge, Amy S. , Schmidt, Remington E. , Bembenek, Brianna M. , Temesgen, Zoey B., Innocenti, Federico , Diasio, Robert B. , Bouchonville, Kelly J. , Wang, Zhiquan , Stroka, Deborah , Largiadèr, Carlo R. , Offer, Steven M.

Mayo Clinic

eLife | April 30, 2024 | Volume: 13 | Issue: No issue available | Pages: No page available

10.7554/elife.94075.3 Get It

Enhancers are critical for regulating tissue-specific gene expression, and genetic variants within enhancer regions have been suggested to contribute to various cancer-related processes, including therapeutic resistance. However, the precise mechanisms remain elusive. Using a well-defined drug-gene pair, we identified an enhancer region for dihydropyrimidine dehydrogenase (DPD, DPYD gene) expression that is relevant to the metabolism of the anti-cancer drug 5-fluorouracil (5-FU). Using reporter systems, CRISPR genome-edited cell models, and human liver specimens, we demonstrated in vitro and vivo that genotype status for the common germline variant (rs4294451; 27% global minor allele frequency) located within this novel enhancer controls DPYD transcription and alters resistance to 5-FU. The variant genotype increases recruitment of the transcription factor CEBPB to the enhancer and alters the level of direct interactions between the enhancer and DPYD promoter. Our data provide insight into the regulatory mechanisms controlling sensitivity and resistance to 5-FU.
Five-Year Outcomes among U.S. Bronchiectasis and NTM Research Registry Patients
Aksamit, Timothy R. , Locantore, Nicholas , Ali, Juzar , Behrman, Megan, Brunton, Amanda E. , Chalmers, Sarah , Choate, Radmila , Dean, Nathan C. , DiMango, Angela, Fraulino, David , Johnson, Margaret M. , Lapinel, N. , McShane, Pamela J. , Miller, Bruce E. , Naureckas, Edward T. , O’Donnell, Anne E., Olivier, Kenneth N., Prusinowski, Elly, Richards, C. , Rhyne, Gloria, Thomashow, Byron, Tino, Gregory , Tsui, K., Varghese, Sumith Abraham, Warren, Heather E., Winthrop, Kevin , Zha, Beth Shoshanna, Addrizzo-Harris, Doreen , Basavaraj, Ashwin , Brunton, Amanda E , Chalmers, Sarah , Choate, Radmila , Dean, Nathan C , Johnson, Margaret M , Maselli, Diego J , McShane, Pamela J , Miller, Bruce E , O'Donnell, Anne E , Olivier, Kenneth N , Restrepo, Marcos I , Richards, Christopher J , Solomon, George M , Tal-Singer, Ruth , Zha, Beth Shoshanna , Addrizzo‐Harris, Doreen , BARKER, ALAN ROBERT , Metersky, Mark L. , Schmid, Andreas, Tal‐Singer, Ruth , Varghese, Sumith Abraham

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | April 26, 2024 | Volume: 210 | Issue: 1 | Pages: 108-118

10.1164/rccm.202307-1165oc | PMID 38668710 Get It

Abstract Rationale Nontuberculous mycobacteria (NTM) are prevalent among patients with bronchiectasis. However, the long-term natural history of patients with NTM and bronchiectasis is not well described. Objectives To assess the impact of NTM on 5-year clinical outcomes and mortality in patients with bronchiectasis. Methods Patients in the Bronchiectasis and NTM Research Registry with ⩾5 years of follow-up were eligible. Data were collected for all-cause mortality, lung function, exacerbations, hospitalizations, and disease severity. Outcomes were compared between patients with and without NTM at baseline. Mortality was assessed using Cox proportional hazards models and the log-rank test. Measurements and Main Results In total, 2,634 patients were included: 1,549 (58.8%) with and 1,085 (41.2%) without NTM at baseline. All-cause mortality (95% confidence interval) at Year 5 was 12.1% (10.5%, 13.7%) overall, 12.6% (10.5%, 14.8%) in patients with NTM, and 11.5% (9.0%, 13.9%) in patients without NTM. Independent predictors of 5-year mortality were baseline FEV1 percent predicted, age, hospitalization within 2 years before baseline, body mass index, and sex (all P &lt; 0.01). The probabilities of acquiring NTM or Pseudomonas aeruginosa were approximately 4% and 3% per year, respectively. Spirometry, exacerbations, and hospitalizations were similar, regardless of NTM status, except that annual exacerbations were lower in patients with NTM (P &lt; 0.05). Conclusions Outcomes, including exacerbations, hospitalizations, rate of loss of lung function, and mortality rate, were similar across 5 years in patients with bronchiectasis with or without NTM.